A5337: Safety and Efficacy of Sirolimus for HIV Reservoir Reduction in Individuals on Suppressive Antiretroviral Therapy

Study Location:

Washington

Topic:

HIV

Clinicaltrials.gov Link:

https://clinicaltrials.gov/ct2/show/NCT02440789?term=a5337&rank=1

IRB#:

Pro00013249

Coordinator:

Anna Wimpelberg

Enrollment:

Open

Trial Period:

Ongoing

When a person becomes infected with HIV the immune system (the system that helps fight infection) is weakened (partly because the number of CD4 cells goes down). Despite successful treatment with anti-HIV therapy, latent reservoirs (infected cells that are not actively producing HIV) remain in the blood and contribute to a process called immune system activation and inflammation in the body. This may contribute to HIV persisting in cells in the body even while taking medications to treat HIV.

  • HIV-infected men and woman, at least 18 years of age
  • Taking anti-HIV medications that have controlled the HIV viral load (“undetectable” levels) for 2 or more years.
    • Protease inhibitors and cobicistat are not allowed on this study.
  • CD4 cell count greater than or equal to 400 cells/mm3
  • No active hepatitis B or C infection, tuberculosis, or shingles
  • No vaccinations in the past 14 days.

Anna Wimpelberg 
202-797-3589
awimpelberg@whitman-walker.org

Categories

Location
Topic

Clinical Trials

NWCS 445: Novel Biomarkers to Shorten TB Treatment

Objectives: Primary: To develop a highly predictive algorithm that identifies TB patients who will be cured by treatment...

Read More

A5349: Rifapentine-containing treatment shortening regimens...

The purpose of this study is to determine whether one or two four-month regimens of tuberculosis treatment are as effective as a...

Read More

A5322: Long-Term Follow-up of Older HIV-infected Adults in...

The A5322 protocol is a long-term observational study, with a planned series of analyses of data to be collected from an...

Read More

P1077FF: Formula Feeding Version of the PROMISE Study...

1077FF is a randomized strategy trial, which is part of the PROMISE studies (1077BF, 1077FF, P1084s, and 1077HS). The Promoting...

Read More

P2001 (DAIDS ID 12026): Evaluating the Pharmacokinetics,...

TB is a major cause of illness and death in women of reproductive age. Pregnant and postpartum women with latent TB are at...

Read More